News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Treated patients had a –0.2 mean change in cUHDRS compared with a –1.0 change in external control data.

The chairman and chief executive officer of NKGen discussed the mechanism behind the company’s NK cell therapy SNK01 and promising early results in patients with PD.

The professor of internal medicine and pediatrics at National Jewish Health discussed updated data from the phase 1/2 AEROW trial of 4D-710.

Ntrust-2 will assess NKX019 in systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

The phase 1/2 GALILEO-1 trial has completed enrollment and a phase 3 trial is planned for 2025.

The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024.

The chairman and chief executive officer of NKGen discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics, discussed trends in precision medicine for cardiovascular indications.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The trial's primary endpoint is improvement on Luminance Dependent Navigation Assessment (LDNA).

Review top news and interview highlights from the week ending July 5, 2024.

First-in-human data with low dose VRON-0200 were presented at the EASL 2024 congress.

The therapy, rAAV-Olig001-ASPA, has shown positive clinical benefits in several interim updates from an ongoing, first-in-human phase 1/2 clinical trial (NCT04833907).

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company has reported data in NMOSD, myasthenia gravis, and necrotizing myopathy over the last several months.

The associate professor of neurology at the Cleveland Clinic Lerner Institute discussed the challenges that will need to be overcome to apply gene therapy to a complex neurological disorder like PD.

The senior researcher at Seattle Children’s discussed advantages of engineered Tregs compared with natural Tregs.

Cartesian also announced that the first patient has been dosed in a separate clinical trial evaluating the CAR-T therapy in systematic lupus erythematosus.

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy.

The associate professor of neurology at the Cleveland Clinic Lerner Institute pointed out that genetic forms of PD may be the best place to start for new therapeutic research.

CGTLive takes a look at the path gene therapies have blazed in leukodystrophies, the challenges they’ve faced, and the road they’ve paved.

The placebo-controlled multidose portion of the SELECT-HD trial included 23 patients with Huntington Disease in total.

The professor in residence for pediatrics at the Sickle Cell Center of Excellence at the University of California discussed gene therapy’s ongoing transformation of the treatment landscape.

Eight patients receiving either TSC-100 or TSC-101 have been disease-free for a median of 10 months of follow-up.